Home › Trial NCT05013554
Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors
- Trial IDNCT05013554
- StatusTerminated
- PhasePhase 1
- Study typeInterventional
- SponsorSanofi
- Enrollment44
- Start date2021-08-16
- ConditionsNeoplasm Malignant · Breast Cancer · Lung Neoplasm Malignant · Gastric Cancer · Neoplasm
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.